{"id":"https://openalex.org/W2547817455","doi":"https://doi.org/10.1080/21678707.2016.1253469","title":"Mogamulizumab in the treatment of cutaneous T cell lymphoma","display_name":"Mogamulizumab in the treatment of cutaneous T cell lymphoma","publication_year":2016,"publication_date":"2016-11-04","ids":{"openalex":"https://openalex.org/W2547817455","doi":"https://doi.org/10.1080/21678707.2016.1253469","mag":"2547817455"},"language":"en","primary_location":{"id":"doi:10.1080/21678707.2016.1253469","doi":"https://doi.org/10.1080/21678707.2016.1253469","is_oa":false,"landing_page_url":"https://doi.org/10.1080/21678707.2016.1253469","pdf_url":null,"source":{"id":"https://openalex.org/S2764525121","display_name":"Expert Opinion on Orphan Drugs","issn_l":"2167-8707","issn":["2167-8707"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","ki-jl-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Orphan Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055349992","display_name":"Frank T. Winsett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank Winsett","raw_affiliation_strings":["Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102001041","display_name":"Xiao Ni","orcid":"https://orcid.org/0000-0002-0154-446X","observed_orcids":["https://orcid.org/0000-0002-0154-446X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiao Ni","raw_affiliation_strings":["Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030460763","display_name":"Madeleine A. Duvic","orcid":"https://orcid.org/0000-0002-8971-4565","observed_orcids":["https://orcid.org/0000-0002-8971-4565"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Madeleine Duvic","raw_affiliation_strings":["Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5030460763"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.19876931,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"4","issue":"12","first_page":"1277","last_page":"1280"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mogamulizumab","display_name":"mogamulizumab","score":1.0},{"id":"https://openalex.org/keywords/cutaneous-t-cell-lymphoma","display_name":"cutaneous T-cell lymphoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/mycosis-fungoides","display_name":"mycosis fungoides","score":0.9990000128746033},{"id":"https://openalex.org/keywords/sezary-syndrome","display_name":"S\u00e9zary syndrome","score":1.0},{"id":"https://openalex.org/keywords/ccr4","display_name":"CCR4","score":0.875},{"id":"https://openalex.org/keywords/vorinostat","display_name":"vorinostat","score":0.8230000138282776},{"id":"https://openalex.org/keywords/treg-depletion","display_name":"Treg depletion","score":0.8550000190734863},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.8650000095367432},{"id":"https://openalex.org/keywords/advanced-disease","display_name":"advanced disease","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7867045402526855},{"id":"https://openalex.org/C2777756187","wikidata":"https://www.wikidata.org/wiki/Q1891209","display_name":"Mycosis fungoides","level":3,"score":0.7390490770339966},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6147046089172363},{"id":"https://openalex.org/C2776780870","wikidata":"https://www.wikidata.org/wiki/Q5196687","display_name":"Cutaneous T-cell lymphoma","level":4,"score":0.5535163879394531},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.37910133600234985},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3729473352432251}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1080/21678707.2016.1253469","doi":"https://doi.org/10.1080/21678707.2016.1253469","is_oa":false,"landing_page_url":"https://doi.org/10.1080/21678707.2016.1253469","pdf_url":null,"source":{"id":"https://openalex.org/S2764525121","display_name":"Expert Opinion on Orphan Drugs","issn_l":"2167-8707","issn":["2167-8707"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","ki-jl-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Orphan Drugs","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/1","display_name":"No poverty","score":0.5299999713897705}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W158917702","https://openalex.org/W1508800210","https://openalex.org/W1570916816","https://openalex.org/W1852312658","https://openalex.org/W1972507334","https://openalex.org/W1980482034","https://openalex.org/W2000150347","https://openalex.org/W2000940176","https://openalex.org/W2002994195","https://openalex.org/W2043729963","https://openalex.org/W2057910076","https://openalex.org/W2065989616","https://openalex.org/W2084136419","https://openalex.org/W2096160655","https://openalex.org/W2102113607","https://openalex.org/W2110890034","https://openalex.org/W2131748990","https://openalex.org/W2136669623","https://openalex.org/W2140608535","https://openalex.org/W2148895451","https://openalex.org/W2152130235","https://openalex.org/W2166075265","https://openalex.org/W2167282403","https://openalex.org/W2185568287","https://openalex.org/W2193839024","https://openalex.org/W2211739901","https://openalex.org/W2281413742","https://openalex.org/W2301355704","https://openalex.org/W2324052799","https://openalex.org/W2349243225","https://openalex.org/W2406416858","https://openalex.org/W4249660526"],"related_works":["https://openalex.org/W4309732251","https://openalex.org/W2885239461","https://openalex.org/W4411611715","https://openalex.org/W2900968609","https://openalex.org/W2911317946","https://openalex.org/W7223157556","https://openalex.org/W4408245324","https://openalex.org/W7166004605","https://openalex.org/W2002994195","https://openalex.org/W7160102204"],"abstract_inverted_index":{"Introduction:":[0],"Cutaneous":[1],"T":[2,20,30,51,77,103,128,145,168,194],"cell":[3,31,52,78,104,129,146,195],"lymphomas":[4],"are":[5,153],"a":[6,24,42,82,113,187],"heterogeneous":[7],"group":[8],"of":[9,15,28,49,75,126,142,157,166,186,190],"malignancies":[10],"characterized":[11,33],"by":[12,34,178],"the":[13,47,67,124,140,155,171,184],"accumulation":[14],"malignantly":[16],"transformed":[17],"skin":[18],"homing":[19],"cells.":[21],"Mycosis":[22],"fungoides,":[23],"typically":[25],"indolent":[26],"form":[27],"cutaneous":[29,50,76,102,127,193],"lymphoma":[32,79],"patches,":[35],"plaques,":[36],"and":[37,39,54,80,161,170],"tumors,":[38],"S\u00e9zary":[40],"syndrome,":[41],"leukemic":[43],"variant,":[44],"make":[45],"up":[46],"majority":[48],"lymphomas,":[53],"prognosis":[55],"in":[56,94,99,123,137,151,174,183],"advanced-stage":[57,87],"disease":[58],"remains":[59],"poor.":[60],"The":[61],"defucosylated":[62],"monoclonal":[63],"antibody,":[64],"mogamulizumab,":[65,179],"targets":[66],"CC":[68],"chemokine":[69],"receptor":[70],"4":[71],"on":[72],"malignant":[73],"cells":[74],"offers":[81],"novel":[83],"approach":[84],"to":[85,121],"treating":[86],"disease.Areas":[88],"covered:":[89],"Mogamulizumab":[90,132],"has":[91,133],"shown":[92],"efficacy":[93,156],"phase":[95,114],"I/II":[96],"clinical":[97],"trials":[98],"patients":[100],"with":[101,106],"lymphoma,":[105],"overall":[107],"response":[108],"rates":[109],"between":[110],"35\u201336.8%.":[111],"Currently,":[112],"III":[115],"trial":[116],"is":[117],"underway":[118],"comparing":[119],"mogamulizumab":[120,158],"vorinostat":[122],"treatment":[125,141,185],"lymphoma.Expert":[130],"opinion:":[131],"already":[134],"been":[135],"approved":[136],"Japan":[138],"for":[139,159],"relapsed/refractory":[143],"adult":[144],"leukemia/lymphoma.":[147],"Clinical":[148],"trials,":[149],"currently":[150],"progress,":[152],"investigating":[154],"advanced":[160],"metastatic":[162],"solid":[163],"tumors.":[164],"Depletion":[165],"regulatory":[167],"cells,":[169],"resulting":[172],"boost":[173],"anti-tumor":[175],"immunity":[176],"caused":[177],"have":[180],"great":[181],"potential":[182],"wide":[188],"range":[189],"malignancies,":[191],"including":[192],"lymphomas.":[196]},"counts_by_year":[],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-11-11T00:00:00"}